Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

The AdventHealth Neuroscience Institute is testing IDP-023 for primary or nonactive secondary progressive multiple sclerosis ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune disorders, with several early- to mid-stage readouts expected this year.

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com . A webcast replay will be made available following the ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...